Recombinant Activated Factor VII: The Delicate Balance between Efficacy and Safety

摘要: Endogenous activated factor VII (FVIIa) plays a crucial role in the effective coagulation process. The clotting drug NovoSeven® (Novo Nordisk A/S, Bagsvaerd, Denmark) is structurally nearly identical to endogenous FVIIa and produced by recombination from baby hamster kidney cell line. Supra-physiologic concentrations of are achieved administration pharmacological doses recombinant (rFVIIa). To generate thrombin, rFVIIa needs either tissue or platelets (tissue factor-independent generation). Consequently, approved for prevention treatment bleeding patients with range congenital hemostatic disorders, mainly hemophilia. Its high efficacy various defects has oriented its application perioperative setting, trauma, ICU patients. Over last five years, estimated number treated rVIIa grown rapidly, off-license indications.